Will Ozempic Bring My Period Back? What the PMOS Evidence Actually Says

The question usually arrives sideways. You started semaglutide for weight, or because your insulin resistance finally got someone's attention, and somewhere in month two you notice you have bled twice in a row for the first time in years. Or the opposite happens: you are four months in, the weight is moving, and the cycle has not budged — and you want to know whether to keep waiting or stop expecting it.

Search the question and you get one number, everywhere: 80%.

That number is real. We traced it. But it has been passed around so many times that the part which decides whether it applies to you has fallen off.

Where the "80%" everyone quotes comes from — and the two words that got dropped

The source is a 2023 study in the Journal of Clinical Medicine by Carmina and Longo, an endocrinology group in Palermo. Twenty-seven women with PCOS — now PMOS, after the 2026 Lancet consensus renamed it — all of them obese, all of them already unsuccessful on a supervised lifestyle programme, were treated with semaglutide at 0.5 mg weekly.

At three months, mean weight loss was 7.6 kg. Around 78% of them lost at least 5% of body weight; those women were classed as responsive and continued to six months, by which point mean loss was 11.5 kg.

Then the sentence everyone quotes: "A total of 80% of responsive patients normalized menstrual cycles."

Two words carry the whole thing. Of responsive. Not 80% of women who took it — 80% of the subset who had already lost meaningful weight on it. Run the arithmetic on the original cohort and it lands closer to three in five of everyone who started. And it was read at six months, not the three months the figure is usually attached to.

Twenty-seven women. Single centre. No control group. That is the entire evidentiary basis for the most-quoted number on this topic.

The same researchers went back with 96 women, and got 52.5%

In July 2026 the same two authors published a larger study, and its title is almost exactly this question: Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome.

Ninety-six women with PMOS and a BMI above 25 completed six months of semaglutide on an individualised dose-escalation regimen. Mean weight loss was 11.3%. Before treatment, 83% had oligomenorrhoea and anovulatory cycles.

After six months, ovulatory cycles were observed in 52.5% of the previously anovulatory women.

That is a larger study, published later, by the same team — and it lands well below 80%. It is not a contradiction. It is a different denominator (everyone, not just responders) and a stricter endpoint (ovulation, not a bleed). It is also the better number, because it is the one that describes the whole room.

What actually predicts whether your cycles return

This is the most useful finding in the 2026 paper and almost nobody repeats it. The response did not spread evenly. It split hard by how much weight the woman was carrying to begin with:

• Overweight, and those with mild obesity: almost 95% achieved menstrual cycle normalisation and ovulation.
• Moderate or severe obesity: 25%.

So the honest answer to "will this bring my period back" is not one percentage. It is closer to: it depends where you are starting from, and the gap between those two groups is enormous.

One caveat worth holding if you are in Asia. Those bands are BMI categories drawn on a European cohort, and PMOS in Asian populations is assessed against lower cutoffs — 23 for overweight, 25 for obesity, rather than 25 and 30. Where you fall on the paper's scale may not be where you fall on your own clinic's.

Bleeding is not the same as ovulating

Most pages on this topic use "my period came back" and "my cycles normalised" as though they were one event. They are not, and the difference matters.

You can bleed without ovulating. The 2026 study specifically assessed ovulatory function, which is why its number is lower and more trustworthy than a count of bleeds would have been. If the reason you care is fertility, ovulation is the endpoint that counts — and it is confirmed with a mid-luteal progesterone, not by the bleed showing up. If the reason you care is endometrial protection, regular shedding matters in its own right.

Worth asking your doctor which one you are actually being told has improved. They are different things on a blood panel.

How long it takes — and why the timelines circulating are not measured

You will see "8 to 16 weeks", "12 weeks on average", "cycles normalise by 20 weeks". We went looking for the primary sources behind those and could not find them. They appear on operator pages and in search summaries, sourced to nothing we could open.

What is measured: both Carmina studies report menstrual and ovulatory outcomes at six months. The 2023 paper read weight at three months, but the menstrual result — the 80% — belongs to the six-month timepoint.

That is not a reason to assume nothing happens before then. It is a reason to be suspicious of anyone quoting you a week number, and a reason not to conclude at month three that it has failed.

If your cycles come back, so does the chance of pregnancy

This is the part that gets left out of the celebratory framing, and it is the one with real consequences.

Semaglutide's label is explicit: "Discontinue OZEMPIC in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide." So a drug that may restore ovulation is also a drug you are told to stop two months before conceiving. If your cycles return and you are not using contraception, that sequencing problem becomes live immediately — and it deserves a conversation before it becomes urgent. We wrote about what actually happens in that two-month gap separately.

The first international consensus guidance on incretins and reproduction arrived in July 2026 — 23 authors, 34 studies — and it is candid about the state of things: the group found usable evidence for only 56.3% of its own research questions.

What we would take from this

Neither Carmina study had a control group, and both were run by the same single centre. That means neither can separate the molecule from the weight loss — and weight loss on its own is long established to restore ovulation in PMOS. So the defensible statement is that ovulatory cycles were associated with six months of semaglutide, not that the drug caused them. Which also means the durability question lands on the weight, not the prescription: a 2024 two-year observational study of women with PCOS who came off semaglutide found the story continues after the injections stop, and we covered what tends to happen then.

If you want the fuller picture of what GLP-1s do and do not do in PMOS, we keep a running read of the 2026 evidence. And if you are weighing whether the dose you are on is the one you need to stay on, that has its own evidence base.

None of this is a recommendation to start, stop or change a medication — that is a prescriber's call, and the useful version of this conversation starts with knowing which driver is actually behind your irregular cycles. Our free assessment reads that in about five minutes.

Sources

• Carmina E, Longo RA. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs. Journal of Clinical Medicine. 2023 Sep 12;12(18):5921. PMID: 37762862.
• Carmina E, Longo RA. Evidence That Semaglutide Represents an Important Tool for Treatment of Irregular Menses and Chronic Anovulation in Women with Polyendocrine Metabolic Ovarian Syndrome. Journal of Clinical Medicine. 2026 Jul 2;15(13):5165. PMID: 42452625.
• Jensterle M, Ferjan S, Janez A. The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study. Frontiers in Endocrinology (Lausanne). 2024;15:1366940. PMID: 38665260.
• Maslin K, Shawe J, Blowers S, et al. Incretin-Based Medications in Women and Reproduction: A Systematic Scoping Review and Consensus Guidelines for Clinical Practice. Obesity Reviews. 2026 Jul 29:e70203. PMID: 42528099.
• Ozempic (semaglutide) US Prescribing Information, Section 8.1 (Pregnancy), revision 5/2026.
• Teede HJ, et al. International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome, 2023.